Skip to main content
Premium Trial:

Request an Annual Quote

Genizon Partners with NDEI to Continue Schizophrenia Studies with Quebec Founder Population

NEW YORK (GenomeWeb News) - Genizon Biosciences said today it has partnered with the Canadian company Neuropsychiatrie, Decouverte & Innovation to conduct further genome-wide research on schizophrenia-related genes Genizon has discovered.
Earlier this year, Genizon identified multiple genes associated with schizophrenia in a genome-wide association study using DNA samples from patients from the Quebec Founder Population.
Under the agreement with NDEI, the company will provide Genizon with a second set of samples from the Quebec Founder Population that it will use for further research.
NDEI was founded in 2002 as a spinoff company of the Centre de Recherche Universite Laval Robert-Giffard.
“We expect the results of these studies to lead to a new generation of safer and more effective treatments tailored to individual schizophrenia patients,” said Michel Maziade, a scientist at the University of Laval, which will provide access to the samples.
Financial terms of the agreement were not released.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.